Liraglutide vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Key Comparison Insights
- Liraglutide is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Liraglutide has stronger research evidence (FDA Approved) compared to CagriSema (Human Trials).
Detailed Comparison
| Attribute | Liraglutide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Liraglutide has 97% homology to native GLP-1 with modifications for extended half-life. It slows gastric emptying, increases insulin secretion, suppresses glucagon, and acts on brain appetite centers to reduce hunger. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | 1.8-3 mg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection daily | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning or evening, consistent daily | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda). | Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment. |
Frequently Asked Questions: Liraglutide vs CagriSema
What is the difference between Liraglutide and CagriSema?
Liraglutide is a weight loss peptide that an fda-approved glp-1 receptor agonist for type 2 diabetes and chronic weight management. the predecessor to semaglutide with daily dosing. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog). the most effective weight loss drug candidate, showing 22.7% body weight reduction in phase 3 trials - superior to any single-agent glp-1. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Liraglutide or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Liraglutide is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Liraglutide and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Liraglutide and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Liraglutide and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.